MUC16 and neoplasm: Early changes in peripheral blood biomarkers other than CA125, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and immune cells, have been investigated in recurrent ovarian cancer as well, although are less accessible in clinical practice.